Marlan D. Walker - Sep 29, 2021 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role
General Counsel
Signature
/s/ Marlan D. Walker
Stock symbol
TXMD
Transactions as of
Sep 29, 2021
Transactions value $
$0
Form type
4
Date filed
10/1/2021, 05:00 PM
Previous filing
Jul 2, 2021
Next filing
Mar 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXMD Restricted Stock Units Award $0 +57.8K $0.00 57.8K Sep 29, 2021 Common Stock 57.8K $0.00 Direct F1, F2
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -100K -100% $0.00* 0 Sep 29, 2021 Common Stock 100K $7.72 Direct F3, F4
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -150K -100% $0.00* 0 Sep 29, 2021 Common Stock 150K $6.26 Direct F3, F5
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -25K -100% $0.00* 0 Sep 29, 2021 Common Stock 25K $6.83 Direct F3, F6
transaction TXMD Non-Qualified Stock Option (right to buy) Other $0 -120K -100% $0.00* 0 Sep 29, 2021 Common Stock 120K $5.16 Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units (RSUs) issued pursuant to the Issuer's stock option exchange program approved by stockholders at the Issuer's 2021 annual meeting (the "Option Exchange Program"). Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 Subject to the reporting person's continuous service, the RSUs will vest in three equal installments annually, beginning September 29, 2022, becoming fully vested on September 29, 2024.
F3 Stock options exchanged for RSUs pursuant to the Option Exchange Program.
F4 Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, and 50,000 shares on the second anniversary date of the grant.
F5 Underlying shares were subject to vesting as follows: 50,000 shares on the first anniversary date of the grant, 50,000 shares on the second anniversary date of the grant, and 50,000 shares on the third anniversary date of the grant.
F6 Underlying shares were subject to vesting as follows: 8,333 shares on the first anniversary date of the grant, 8,333 shares on the second anniversary date of the grant, and 8,334 shares on the third anniversary date of the grant.
F7 Underlying shares were subject to vesting as follows: 40,000 shares on the first anniversary date of the grant, 40,000 shares on the second anniversary date of the grant, and 40,000 shares on the third anniversary date of the grant.